<DOC>
	<DOCNO>NCT00063076</DOCNO>
	<brief_summary>The goal clinical research study find effective dose Targretin® ( bexarotene ) Gel 1 % give patient treatment alopecia areata . The safety tolerability drug also study . Objectives : 1 . Determine safety tolerability Targretin® Gel 1 % treatment patient alopecia areata . 2 . Determine efficacy Targretin® Gel 1 % treatment patient alopecia areata .</brief_summary>
	<brief_title>Phase II Randomized Bilateral Comparison Topical Targretin Gel 1 % Alopecia Areata</brief_title>
	<detailed_description>Targretin® ( bexarotene ) Gel 1 % synthetic vitamin A compound approve topical treatment oral treatment cutaneous T cell lymphoma ( CTCL ) . Vitamin A compound influence growth skin cell , cause death T-cells . Researchers hope bexarotene may get rid T-cells around hair follicle AA ( alopecia areata ) lesion . Before treatment start , patient complete medical history brief physical exam . Researchers ask alopecia disease history , date first diagnosis , early treatment response . Blood test ( 4 teaspoon ) perform end treatment . Additional blood test do need . Women able child must negative blood pregnancy test within 7 day start treatment . Blood pregnancy test must repeat month receive treatment . Participants study randomly assign ( toss coin ) treat alopecia areata lesion one half head . Half participant leave side treat half right side treat . Sealed envelope give participant , tell side head treat . The half head remain untreated serve control . Patients treat alopecia lesion one-half head include facial hair designate investigator . The half head control ( untreated ) alopecia lesion . Up 5 index lesion treatment 5 control lesion designate baseline follow measure study . Patients treat Targretin® gel 1 % dose escalation regimen start every day . At start Week 3 patient begin application twice day application tolerate . Patients continue BID dosing , tolerate , unless investigator determines increase application frequency may benefit patient patient agree comply . Patients see baseline week 2 , 4 , 8 , 12 , 16 , 20 , 24 4-week follow-up . Telephone evaluation do week 1 need . Study visit evaluation safety efficacy make Week 2 4 start treatment every 4 week Week 24 . Telephone safety evaluation also make Week 1 time need . Skin irritation change health study may require participant stop treatment withdraw study . At withdrawal study , 4 teaspoon blood drawn . The total study duration 24 Weeks 4-week follow-up period . At 4-week follow-up visit , physical exam , include measurement vital sign weight perform . An evaluation treat untreated side head perform . Patients show response 6 month ( 24 week ) give option continue therapy additional 6 month able apply medication side head . Patients come every 2 month ( 3 additional visit ) examination study evaluation irritation , hair loss , hair thickness , measurement lesion , physician 's global assessment , evaluation hair re-growth . The dose adjustment withdrawal treatment apply 6-month period . Every 2 month , blood ( 2 tablespoon ) draw pregnancy test look triglyceride ( fat ) level complete blood cell count . This investigational study . Targretin® Gel 1 % commercially available approve FDA use treatment cutaneous lesion patient CTCL . Initially 42 participant enrol study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>1 . Clinical diagnosis alopecia areata , alopecia totalis , alopecia universalis . 2 . Patients must 18 year age participate . 3 . Patients alopecia areata must least two distinct alopecia areata patch &gt; 1.0 cm diameter , one locate right leave side scalp . Patients alopecia totalis universalis distinct alopecia patch complete total alopecia side scalp . Patients alopecia totalis universalis one side scalp treat . The patient must agree treat one side scalp drug , photo take , return followup visit . 4 . They must also agree practice two reliable form contraception ( hormonal , IUD , double barrier ) use simultaneously unless abstinence choose method entire period treatment least one month treatment discontinue . 5 . Men sexual partner childbearing potential pregnant must use condom sexual intercourse Targretin® gel therapy one month last application . 6 . Patients ask voluntarily contribute pre post biopsy research study ( 3 mm punch biopsy hematoxylin eosin ( H &amp; E ) stain immunohistochemistry Tcells ) . However , failure consent biopsy exclude study . 7 . Patients sign informed consent . 1 . Must topical treatment alopecia areata PUVA ( psoralen + UVA ) therapy least two week . 2 . Must discontinue intralesional steroid systemic therapy immunosuppressive may affect alopecia areata least four week . Patients chronic oral steroid eligible study . 3 . Women pregnant breastfeeding exclude . The pregnancy test sensitive least 25 mlU/ml . 4 . Patients hepatitis , HIV serious infection exclude . 5 . Known hypersensitivity Targretin® drug retinoid ingredient study medication . 6 . Patients must participate investigational drug study within 4 week entry . 7 . Patients Hbg &lt; 9.5 g/dL , WBC &lt; 2,500 K/ul , Platelets &lt; 100 K/ul , TSH &gt; 5.5 &lt; 0.5 mcU/mL , T4 &lt; 0.9 &gt; 1.8 g/dl , fast triglyceride level &gt; 350 mg/dl eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Alopecia Areata</keyword>
	<keyword>Alopecia Totalis</keyword>
	<keyword>Alopecia Universalis</keyword>
	<keyword>Targretin Gel</keyword>
</DOC>